



PerkinElmer acquires antibody and reagent leader BioLegend for \$5.25 B

27 July 2021 | News

The transaction will be the largest in US-based PerkinElmer's history

PerkinElmer, Inc. has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately \$5.25 billion in a combination of cash and stock, subject to certain adjustments.

BioLegend provides its academic and biopharmaceutical customers with best-in-class antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing.

The transaction will be the largest in US-based PerkinElmer's history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.

Privately-held BioLegend has more than 700 employees based primarily in the U.S., with estimated 2022 revenues of \$380 million. Upon joining PerkinElmer, BioLegend will expand PerkinElmer's existing life science franchise into new segments, and its state-of-the-art campus in San Diego, California will become PerkinElmer's global Center of Excellence (CoE) for research reagent content development for the combined company.

Commenting on the agreement to acquire BioLegend, Prahlad Singh, president and chief executive officer of PerkinElmer, said: "We are thrilled to have the opportunity to bring our technologies and innovative cultures together to create seamless solutions to push science and discovery forward. We believe joining our teams presents an incredible opportunity to accelerate discoveries that help life science researchers leverage ever-developing technologies and novel approaches to better understand and fight disease."